Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial

Annals of Oncology

Volumn 16, Issue 6, 2005, Pages 878-886

  Comella, Pasquale ^a   Massidda, B ^b   Filippelli, G ^c   Palmeri, S ^d   Natale, D ^e   Farris, A ^f   De Vita, F ^g   Buzzi, F ^e   Tafuto, S ^h   Maiorino, L ⁱ   Mancarella, S ^e   Leo, S ^j   Lorusso, V ^k   De Lucia, L ^l   Roselli, M ^m  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c City Hopsital ^*  (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e City Hospital   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h City Hospital   (Italy)

ⁱ San Gennaro Hospital   (Italy)

^j Referral Cancer Center of Basilicata   (Italy)

^k National Tumour Institute   (Italy)

^l City Hospital   (Italy)

^m UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

5 fluorouracil; Irinotecan; Metastatic colorectal carcinoma; Oxaliplatin; Randomized trial

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PREFERENCE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAIR LOSS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROPATHY; NEUTROPENIA; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 21344459245     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi185     Document Type: Article

References (37)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
3. Abad A, Garcia P, Gravalos C et al. Sequential methotrexate, 5-fluorouracil (5FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer 1995; 75: 1238-1244.
4. Glimelius B. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-250.
5. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775.
6. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 1997; 15: 808-815.
7. Köhne C-H, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer. European Organization of Research and Treatment of Cancer Gastrointestinal Group study 40952. J Clin Oncol 2003; 21: 3721-3728.
8. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
9. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
10. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
11. Comella P, Crucitta E, De Vita F et al. Addition of either irinotecan or methotrexate to bolus fluorouracil and high-dose leucovorin every two weeks in advanced colorectal carcinoma: A randomized study of the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13: 866-873.
12. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071.
13. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16: 2739-2744.
14. Díaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998; 9: 105-108.
15. Machover D, Díaz-Rubio E, De Gramont A et al. Two consecutive phase II study of oxaliplatin (L-OHP) for the treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
16. Fischel J-L, Etienne M-C, Formento P, Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data. Clin Cancer Res 1998; 4: 2529-2535.
17. Brienza S, Besmaine MA, Soulie P et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU pre-treated patients with advanced colorectal cancer (ACRC): Results from the European compassionate use program. Ann Oncol 1999; 10: 1311-1316.
18. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trials. J Clin Oncol 2003; 21: 2059-2069.
19. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
20. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
21. Ravaioli A, Marangolo M, Pasquini E et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002; 20: 2545-2550.
22. Zori Comba A, Blajman C, Richardet E et al. A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37: 1006-1013.
23. Hochster HS, Chachoua A, Speyer J et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first line therapy for patients with advanced colorectal cancer. J Clin Oncol 2003; 21: 2703-2707.
24. Sørbye H, Glimelius B, Berglund A et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-38.
25. Comella P. Randomized trial comparing the addition of either oxaliplatin or irinotecan to high-dose folinic acid and 5-fluorouracil i.v. bolus every two weeks in metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group study (SICOG 0103). Clin Colorectal Cancer 2003; 3: 186-189.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
27. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.
28. Simon R. Design and conduct of clinical trials. In De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, 4th edition. Philadelphia, PA: JB Lippincott Co. 1993; 418-440.
29. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among experimental treatments and a control in clinical trials. Biometrics 1989; 45: 537-547.
30. Cochran WG. Some methods for strengthening the common chi-square test. Biometrics 1954; 10: 417-451.
31. Kaplan ES, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 557-580.
32. Mantel N. Evaluation of survival data and two new ranks of order statistics arising in its considerations. Cancer Chemother Rep 1966; 50: 163-170.
33. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
34. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
35. Punt CJA. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459.
36. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin plus the same treatment combined with either oxaliplatin or CPT-11. Ann Oncol 2004; 15: 545-549.
37. Buyse M, Thirion P, Carlson RW et al. Relation between tumor response to first-line chemotherapy and survival in advanced colorecal cancer: A meta-analysis. Lancet 2000; 356: 373-378.